Nov. 3 at 12:50 PM
$FBLG The company is advancing its pipeline:
It announced “positive IND-enabling updates” from its psoriasis program, showing its human dermal fibroblast spheroids approach may be viable.
It’s pushing manufacturing efforts of its lead product candidate CYWC628 (for diabetic foot ulcers) toward a Phase 1/2 clinical trial, planned in Q1 2026.
Works are underway on its platforms for other indications (psoriasis with CYPS317, multiple sclerosis with CYMS101) and a bone-marrow organoid program.
The company holds 270+ issued or pending patents in fibroblast-based therapeutics.
It is implementing cost-efficient measures to reduce operating expenses and focus on “near-term pipeline priorities”.
Clear upcoming milestones:
Complete manufacturing training runs and confirm sterility of CYWC628 by end of 2025.
Initiate the Phase 1/2 trial in Australia for CYWC628 in Q1 2026.
Complete manufacturing under FDA cGMP for CYWC628.
Submit INDs for the psoriasis and MS programs.
